blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3442945

EP3442945 - TETRAHYDROISOQUINOLINE DERIVATIVES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.05.2021
Database last updated on 31.05.2024
FormerThe patent has been granted
Status updated on  05.06.2020
FormerGrant of patent is intended
Status updated on  06.02.2020
FormerRequest for examination was made
Status updated on  18.01.2019
FormerThe international publication has been made
Status updated on  20.10.2017
Formerunknown
Status updated on  11.04.2017
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
UCB Biopharma SRL
Allée de la Recherche 60
1070 Brussels / BE
[2020/28]
Former [2020/02]For all designated states
UCB Biopharma SRL
Allé de la Recherche 60
1070 Brussels / BE
Former [2019/08]For all designated states
UCB Biopharma SPRL
60, Allée de la Recherche
1070 Brussels / BE
Inventor(s)01 / ATES, Ali
c/o IP Department
UCB Biopharma SPRL
60 Allée de la Recherche
1070 Brussels / BE
02 / JNOFF, Eric
c/o IP Department
UCB Biopharma SPRL
60 Allée de la Recherche
1070 Brussels / BE
03 / PROVINS, Laurent
c/o IP Department
UCB Biopharma SPRL
60 Allée de la Recherche
1070 Brussels / BE
04 / VALADE, Anne
c/o IP Department
UCB Biopharma SPRL
60 Allée de la Recherche
1070 Brussels / BE
05 / HALL, Adrian
c/o IPD
UCB Biopharma SPRL
60 Allée de la Recherche
1070 Brussels / BE
 [2019/08]
Representative(s)UCB Intellectual Property
c/o UCB Biopharma SRL
Intellectual Property Department
Allée de la Recherche 60
1070 Brussels / BE
[2020/28]
Former [2019/08]UCB Intellectual Property
c/o UCB Biopharma SPRL
Intellectual Property Department
Allée de la Recherche 60
1070 Brussels / BE
Application number, filing date17714837.607.04.2017
[2019/08]
WO2017EP58422
Priority number, dateEP2016016501213.04.2016         Original published format: EP 16165012
[2019/08]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017178377
Date:19.10.2017
Language:EN
[2017/42]
Type: A1 Application with search report 
No.:EP3442945
Date:20.02.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 19.10.2017 takes the place of the publication of the European patent application.
[2019/08]
Type: B1 Patent specification 
No.:EP3442945
Date:08.07.2020
Language:EN
[2020/28]
Search report(s)International search report - published on:EP19.10.2017
ClassificationIPC:C07D217/06, C07D401/06, C07D403/06, A61K31/472
[2019/08]
CPC:
C07D401/06 (EP,EA,US); C07D471/04 (EP,EA,US); A61P21/02 (EP);
A61P25/00 (EP); A61P25/14 (EP); A61P25/16 (EP);
A61P25/18 (EP); A61P25/20 (EP); A61P25/28 (EP);
A61P25/30 (EP); A61P43/00 (EP); C07D217/06 (EP,EA,US);
C07D403/06 (EP,EA,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/08]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:TETRAHYDROISOCHINOLIN DERIVATE[2020/04]
English:TETRAHYDROISOQUINOLINE DERIVATIVES[2019/08]
French:DERIVES DE TETRHYDROISOQUINOLINES[2020/04]
Former [2019/08]TETRAHYDROISOCHINOLINDERIVATE
Former [2019/08]DÉRIVÉS DE TÉTRAHYDROISOQUINOLÉINE
Entry into regional phase13.11.2018National basic fee paid 
13.11.2018Designation fee(s) paid 
13.11.2018Examination fee paid 
Examination procedure13.11.2018Examination requested  [2019/08]
13.11.2018Date on which the examining division has become responsible
07.05.2019Amendment by applicant (claims and/or description)
07.02.2020Communication of intention to grant the patent
27.05.2020Fee for grant paid
27.05.2020Fee for publishing/printing paid
27.05.2020Receipt of the translation of the claim(s)
Opposition(s)09.04.2021No opposition filed within time limit [2021/24]
Fees paidRenewal fee
30.04.2019Renewal fee patent year 03
30.04.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.04.2017
AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
IE07.04.2021
LU07.04.2021
[2024/22]
Former [2023/33]HU07.04.2017
AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
IE07.04.2021
LU07.04.2021
Former [2023/30]AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
IE07.04.2021
LU07.04.2021
Former [2022/23]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
IE07.04.2021
LU07.04.2021
Former [2022/21]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
PT09.11.2020
IE07.04.2021
LU07.04.2021
Former [2022/10]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
PT09.11.2020
LU07.04.2021
Former [2022/04]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
LU07.04.2021
Former [2021/50]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/36]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/28]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/25]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/22]AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SE08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/21]AT08.07.2020
DK08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
NL08.07.2020
PL08.07.2020
RS08.07.2020
SE08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/17]AT08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
NL08.07.2020
PL08.07.2020
RS08.07.2020
SE08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/10]AT08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
PL08.07.2020
RS08.07.2020
SE08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/09]AT08.07.2020
FI08.07.2020
LT08.07.2020
SE08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
PT09.11.2020
Former [2021/08]FI08.07.2020
LT08.07.2020
SE08.07.2020
BG08.10.2020
NO08.10.2020
PT09.11.2020
Former [2021/07]FI08.07.2020
LT08.07.2020
NO08.10.2020
Cited inInternational search[A]WO2006020049  (AMR TECHNOLOGY INC [US], et al) [A] 1-20 * claim 1 *;
 [AP]WO2016055479  (UCB BIOPHARMA SPRL [BE]) [AP] 1-20* RN = 1904660-48-5;; claim 1 *;
 [A]  - P. JEFFREY CONN ET AL, "Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders", NATURE REVIEWS DRUG DISCOVERY, (20090101), vol. 8, no. 1, doi:10.1038/nrd2760, ISSN 1474-1776, pages 41 - 54, XP055057164 [A] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1038/nrd2760
by applicantWO2008109336
 WO2013051869
 WO2014193781
 WO2016055482
 WO2016055479
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.